Research programme: Cannabidiol therapeutics - Phytecs
Alternative Names: 4'-F-CBD; Fluorinated cannabidiol; HUF 102; HUF 103Latest Information Update: 28 Sep 2020
At a glance
- Originator Universidade Federal do Rio Grande do Sul; University of Sao Paulo; Yissum Research Development Company
- Class Anxiolytics; Cannabinoids
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Depressive disorders; Obsessive-compulsive disorders; Psychotic disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Depressive disorders in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Obsessive-compulsive-disorders in USA